NCT02235259View on ClinicalTrials.gov

Efficacy and Safety of XG-104 for the Treatment of Dry Eye

PHASE2CompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Dry Eye
Interventions
DRUG

XG-104

Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy

DRUG

Placebo

Trial Locations (1)

01810

Andover Eye Associates, Andover

All Listed Sponsors
lead

Xigen SA

INDUSTRY

NCT02235259 - Efficacy and Safety of XG-104 for the Treatment of Dry Eye | Biotech Hunter | Biotech Hunter